**Proteins** 



# **Product** Data Sheet

# PCSK9 Protein, Mouse (HEK293, His, solution)

Cat. No.: HY-P71189

Synonyms: Proprotein Convertase Subtilisin/Kexin Type 9; Neural Apoptosis-Regulated Convertase 1;

NARC-1; Proprotein Convertase 9; PC9; Subtilisin/Kexin-Like Protease PC9; Pcsk9; Narc1

Species: Mouse Source: HEK293

Accession: Q80W65 (Q35-Q155&S156-Q694)

Gene ID: 100102

Molecular Weight: 17-19 & 60-66 kDa

## **PROPERTIES**

AA Sequence	0.0.5.0.0.7.5.5.1			A T E D D C C W E A	
	QDEDGDYEEL	MLALPSQEDG	LADEAAHVAT	ATFRRCSKEA	
	WRLPGTYIVV	LMEETQRLQI	EQTAHRLQTR	AARRGYVIKV	
	LHIFYDLFPG	FLVKMSSDLL	GLALKLPHVE	YIEEDSFVFA	
	QSIPWNLERI	IPAWHQTEED	RSPDGSSQVE	VYLLDTSIQG	
	AHREIEGRVT	ITDFNSVPEE	DGTRFHRQAS	KCDSHGTHLA	
	GVVSGRDAGV	AKGTSLHSLR	VLNCQGKGTV	SGTLIGLEFI	
	RKSQLIQPSG	PLVVLLPLAG	GYSRILNAAC	RHLARTGVVL	
	VAAAGNFRDD	ACLYSPASAP	EVITVGATNA	QDQPVTLGTL	
	GTNFGRCVDL	FAPGKDIIGA	SSDCSTCFMS	QSGTSQAAAH	
	VAGIVARMLS	REPTLTLAEL	RQRLIHFSTK	DVINMAWFPE	
	DQQVLTPNLV	ATLPPSTHET	GGQLLCRTVW	SAHSGPTRTA	
	TATARCAPEE	ELLSCSSFSR	SGRRRGDWIE	AIGGQQVCKA	
	LNAFGGEGVY	AVARCCLVPR	ANCSIHNTPA	ARAGLETHVH	
	CHQKDHVLTG	CSFHWEVEDL	SVRRQPALRS	RRQPGQCVGH	
	QAASVYASCC	HAPGLECKIK	EHGISGPSEQ	VTVACEAGWT	
	LTGCNVLPGA	SLTLGAYSVD	NLCVARVHDT	ARADRTSGEA	
	TVAAAICCRS	RPSAKASWVQ			
Biological Activity	The enzyme activity of this recombinant protein is testing in progress, we cannot offer a guarantee yet.				
Appearance	Solution.				
7.pp=========	octation.				
Formulation	Supplied as a 0.2 μm filtered solution of 50 mM HEPES, 150 mM NaCl, 20% Glycerol, pH 7.4.				
Endotoxin Level	<1 EU/μg, determined by LAL method.				
	2 20/PO) 4000				
Reconsititution	N/A				
Storage & Stability	Stored at -80°C for 1 year	Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for			
	•	extended storage. Avoid repeated freeze-thaw cycles.			

Page 1 of 2 www. Med Chem Express. com Shipping

Shipping with dry ice.

### **DESCRIPTION**

### Background

The PCSK9 protein plays a pivotal role in the intricate regulation of plasma cholesterol homeostasis. It engages with members of the low-density lipid receptor family, including low-density lipoprotein receptor (LDLR), very low-density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER), and apolipoprotein receptor 2 (LRP8/APOER2), facilitating their degradation within intracellular acidic compartments. Operating through a non-proteolytic mechanism, PCSK9 enhances the degradation of hepatic LDLR via a clathrin LDLRAP1/ARH-mediated pathway and may impede LDLR recycling from endosomes to the cell surface, directing it to lysosomes for degradation. Moreover, PCSK9 induces ubiquitination of LDLR, leading to subsequent degradation, and inhibits the intracellular degradation of APOB through the autophagosome/lysosome pathway, independent of LDLR. Additionally, PCSK9 is implicated in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway, hinders epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by increasing its proteasomal degradation, and modulates neuronal apoptosis by regulating LRP8/APOER2 levels and related anti-apoptotic signaling pathways.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA